JPWO2021029430A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021029430A5 JPWO2021029430A5 JP2021539312A JP2021539312A JPWO2021029430A5 JP WO2021029430 A5 JPWO2021029430 A5 JP WO2021029430A5 JP 2021539312 A JP2021539312 A JP 2021539312A JP 2021539312 A JP2021539312 A JP 2021539312A JP WO2021029430 A5 JPWO2021029430 A5 JP WO2021029430A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- composition according
- benzo
- quinoline
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 3
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 3
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 3
- REOHQDNGVJIIPS-WLHGVMLRSA-N 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 REOHQDNGVJIIPS-WLHGVMLRSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018460 Feeding disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150733A JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2019/031895 | 2019-08-13 | ||
| PCT/JP2019/031895 WO2021029020A1 (ja) | 2019-08-13 | 2019-08-13 | 経口医薬組成物 |
| PCT/JP2020/030777 WO2021029430A1 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150733A Division JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021029430A1 JPWO2021029430A1 (cg-RX-API-DMAC7.html) | 2021-02-18 |
| JPWO2021029430A5 true JPWO2021029430A5 (cg-RX-API-DMAC7.html) | 2022-06-22 |
| JP7148733B2 JP7148733B2 (ja) | 2022-10-05 |
Family
ID=74569440
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (cg-RX-API-DMAC7.html) | 2019-08-13 | 2019-08-13 | |
| JP2021539312A Active JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
| JP2022150733A Active JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (cg-RX-API-DMAC7.html) | 2019-08-13 | 2019-08-13 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
| JP2022150733A Active JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Country Status (15)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021029020A1 (cg-RX-API-DMAC7.html) * | 2019-08-13 | 2021-02-18 | ||
| WO2023145120A1 (ja) * | 2022-01-31 | 2023-08-03 | 住友精化株式会社 | 薬物放出制御製剤用組成物及び薬物放出制御製剤 |
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| JP2025539974A (ja) * | 2023-03-29 | 2025-12-11 | メルク・シャープ・アンド・ドーム・エルエルシー | 放出制御型pde10a製剤 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (cg-RX-API-DMAC7.html) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| TWI636784B (zh) * | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途 |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| AR088372A1 (es) * | 2011-10-19 | 2014-05-28 | Otsuka Pharma Co Ltd | Solucion para administracion oral |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| CN112402421A (zh) * | 2012-10-25 | 2021-02-26 | 大塚制药株式会社 | 含有依匹唑派或其盐的预防和/或治疗剂 |
| CN106667969A (zh) * | 2017-02-23 | 2017-05-17 | 佛山市弘泰药物研发有限公司 | 一种依匹哌唑缓释胶囊及其制备方法 |
| JP6886654B2 (ja) * | 2017-04-11 | 2021-06-16 | 学校法人帝京大学 | 抗カンジダ活性組成物 |
| JPWO2021029020A1 (cg-RX-API-DMAC7.html) * | 2019-08-13 | 2021-02-18 |
-
2019
- 2019-08-13 JP JP2021539751A patent/JPWO2021029020A1/ja not_active Withdrawn
- 2019-08-13 WO PCT/JP2019/031895 patent/WO2021029020A1/ja not_active Ceased
-
2020
- 2020-08-13 US US17/634,758 patent/US20220273647A1/en not_active Abandoned
- 2020-08-13 KR KR1020227007743A patent/KR20220046624A/ko active Pending
- 2020-08-13 MX MX2022001758A patent/MX2022001758A/es unknown
- 2020-08-13 KR KR1020227007745A patent/KR20220046625A/ko active Pending
- 2020-08-13 AU AU2020328351A patent/AU2020328351B2/en active Active
- 2020-08-13 CA CA3150827A patent/CA3150827A1/en active Pending
- 2020-08-13 JP JP2021539312A patent/JP7148733B2/ja active Active
- 2020-08-13 CN CN202080056806.6A patent/CN114222575A/zh active Pending
- 2020-08-13 EP EP20853069.1A patent/EP4015002A4/en active Pending
- 2020-08-13 EP EP20853189.7A patent/EP4015001A4/en active Pending
- 2020-08-13 PH PH1/2022/550349A patent/PH12022550349B1/en unknown
- 2020-08-13 US US17/634,791 patent/US20220280418A1/en not_active Abandoned
- 2020-08-13 PH PH1/2022/550347A patent/PH12022550347A1/en unknown
- 2020-08-13 WO PCT/JP2020/030776 patent/WO2021029429A1/ja not_active Ceased
- 2020-08-13 MY MYPI2022000781A patent/MY208267A/en unknown
- 2020-08-13 TW TW114101321A patent/TWI923262B/zh active
- 2020-08-13 TW TW109127609A patent/TWI870442B/zh active
- 2020-08-13 JP JP2021539311A patent/JP7110495B2/ja active Active
- 2020-08-13 TW TW109127608A patent/TWI870441B/zh active
- 2020-08-13 IL IL290469A patent/IL290469B2/en unknown
- 2020-08-13 CN CN202080056803.2A patent/CN114222562A/zh active Pending
- 2020-08-13 TW TW114101017A patent/TWI915169B/zh active
- 2020-08-13 BR BR112022002433A patent/BR112022002433A2/pt unknown
- 2020-08-13 AU AU2020327792A patent/AU2020327792B2/en active Active
- 2020-08-13 CA CA3150751A patent/CA3150751A1/en active Pending
- 2020-08-13 WO PCT/JP2020/030777 patent/WO2021029430A1/ja not_active Ceased
- 2020-08-13 MY MYPI2022000768A patent/MY208261A/en unknown
- 2020-08-13 BR BR112022002436A patent/BR112022002436A2/pt unknown
- 2020-08-13 MX MX2022001759A patent/MX2022001759A/es unknown
-
2022
- 2022-02-09 IL IL290472A patent/IL290472A/en unknown
- 2022-02-10 MX MX2025006039A patent/MX2025006039A/es unknown
- 2022-02-23 ZA ZA2022/02320A patent/ZA202202320B/en unknown
- 2022-02-23 ZA ZA2022/02319A patent/ZA202202319B/en unknown
- 2022-07-13 JP JP2022112389A patent/JP2022132411A/ja active Pending
- 2022-09-21 JP JP2022150733A patent/JP7635187B2/ja active Active
-
2024
- 2024-08-26 US US18/815,060 patent/US20250127776A1/en active Pending
- 2024-09-18 US US18/888,277 patent/US20250057835A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020427A patent/JP2025072595A/ja active Pending
- 2025-02-25 JP JP2025027501A patent/JP2025074104A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180531A5 (cg-RX-API-DMAC7.html) | ||
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| Molinuevo et al. | Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias | |
| Liu et al. | Exploration of restless legs syndrome under the new concept: A review | |
| Mizuno et al. | Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease | |
| Wine et al. | Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions | |
| JPWO2021029429A5 (cg-RX-API-DMAC7.html) | ||
| JP2003503450A5 (cg-RX-API-DMAC7.html) | ||
| Raybuck et al. | Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. | |
| Roux et al. | Medication effects on sleep | |
| Manconi et al. | Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome | |
| Cass et al. | Protection by GDNF and other trophic factors against the dopamine‐depleting effects of neurotoxic doses of methamphetamine | |
| Neubauer | The evolution and development of insomnia pharmacotherapies | |
| CN103356620A (zh) | 双苄基异喹啉类化合物或其在药学上可接受的盐治疗和改善抑郁症状的新用途 | |
| Gong et al. | Exercise Reduces Morphine‐Induced Hyperalgesia and Antinociceptive Tolerance | |
| Byrne et al. | Restless legs syndrome: diagnosis and review of management options | |
| Sims et al. | Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? | |
| Kokturk et al. | Tryptophan metabolism and sleep | |
| Castaneda et al. | A review of the effects of moderate alcohol intake on psychiatric and sleep disorders | |
| Chen et al. | Preparation of aripiprazole-poly (methyl vinyl ether-co-maleic anhydride) nanocomposites via supercritical antisolvent process for improved antidepression therapy | |
| Im et al. | Management of sleep disorders in stroke | |
| Janas-Kozik et al. | The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2–pharmacological properties and safety of use | |
| CN1111408C (zh) | 药物滥用疾病治疗中的吡啶基-和嘧啶基-哌嗪类化合物 | |
| WO2023230303A1 (en) | Treatment of cognitive decline related to anesthesia and sedation | |
| Tembe et al. | Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: a randomized double blind multicentric clinical trial |